Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up on Analyst Upgrade

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price gapped up before the market opened on Friday after Raymond James raised their price target on the stock from $51.00 to $56.00. The stock had previously closed at $29.90, but opened at $32.25. Raymond James currently has an outperform rating on the stock. Dianthus Therapeutics shares last traded at $30.56, with a volume of 27,707 shares.

Other equities research analysts have also recently issued research reports about the company. Wedbush dropped their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an “outperform” rating and a $58.00 target price on the stock. Oppenheimer assumed coverage on shares of Dianthus Therapeutics in a report on Thursday, October 3rd. They set an “outperform” rating and a $48.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Thursday, September 26th. Finally, Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $45.86.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after acquiring an additional 384,182 shares during the period. Bank of New York Mellon Corp increased its stake in Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after buying an additional 72,509 shares during the last quarter. SG Americas Securities LLC increased its stake in Dianthus Therapeutics by 104.0% in the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock valued at $242,000 after buying an additional 4,506 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. increased its stake in Dianthus Therapeutics by 281.9% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock valued at $1,022,000 after buying an additional 29,159 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in Dianthus Therapeutics by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after buying an additional 8,473 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Performance

The business’s 50-day moving average price is $27.75 and its 200 day moving average price is $26.51. The company has a market cap of $853.49 million, a P/E ratio of -5.25 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.28 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.